Marco Meglio

The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.

RapidAI identified 98% of LVOs compared to 74% by Viz LVO, while also correctly identifying 94% of LVO-negative cases compared to 91% for Viz.

The pediatric neurologist provided a clinical overview of the advances and roadblocks of gene therapy in neuromuscular disorders, which will be highlighted at the 2025 MDA Clinical & Scientific Conference.

Propranolol showed a stronger protective effect against ischemic stroke compared to other beta-blockers, such as metoprolol and timolol, possibly due to its unique pharmacological profile.

ANGEL-TNK demonstrated Tenecteplase's potential to enhance microcirculation post-thrombectomy, reducing brain tissue damage from inadequate blood flow.

The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]

Over a 3-month period, galcanezumab treatment reduced definite dizzy days from 17.9 to 6.6, compared to 18.0 to 12.5 in the placebo group

The approval was based on data from the ADAPT-PD trial, a prospective study that laid the foundation for aDBS use in a real-world clinical environment.

Symbravo showed a statistically significant greater migraine treatment response compared to prior oral CGRP inhibitors (P <0.001), with 47.9% of patients reporting 2-hour pain freedom for most attacks versus 1.0% with oral CGRPs

The associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the history of the ACTRIMS Forum.

Pathogenic variants in the CACNA1A, ATP1A2, and SCN1A genes were associated with a higher risk of migraine, particularly in heterozygous carriers of loss-of-function and neutral variants.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Julie Flygare, JD. [LISTEN TIME: 16 minutes]

More than 90% of participants had Parkinson's disease mild cognitive impairment (PD-MCI), highlighting TAK-071’s potential for treating early-stage cognitive decline in Parkinson disease.

A pair of lead neurologists at Baptist Health South Florida provided commentary on some of the promising developments expected to emerge in neurology over the coming months.

Zorevunersen, an antisense oligonucleotide, is currently being evaluated in a phase 3 registrational trial, with data expected in the second half of 2027.

The FDA has assigned a PDUFA action date of August 19, 2025, and if approved, vatiquinone would be the first therapy for pediatric patients with Friedreich ataxia.

Total healthcare costs were 14% higher for patients with potentially inappropriate medication use in the Alzheimer-insomnia cohort, with significant contributions from inpatient care, ambulatory care, and pharmacy costs.

The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]

After 90 days of treatment, investigators observed positive findings on microdystrophin expression, as well as reductions in markers of muscle injury and stress, and muscle breakdown and dystrophic regeneration.

Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.

Jonathon Parker, MD, PhD, an assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona, provided commentary on the promise and roadblocks behind stem cell approaches in epilepsy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on chronic demyelinating inflammatory polyneuropathy (CIDP).

Also known as SNK01, the novel NK cell manufacturing technology enables large-scale ex vivo production and expansion of NK cells.

Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.

The pharmacokinetic exposure for both sumatriptan and zavegepant was comparable when coadministered, with all ratios remaining within the bioequivalence range of 80%-125%.

Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.

Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.

Expected to conclude in late 2026, the trial will feature 30 patients with Jordan’s syndrome, aged 9-45 years, who will be tested for a 24-week treatment period.